The first international standards for the design and reporting of clinical trials involving artificial intelligence have been announced in a move experts hope will tackle the issue of overhyped studies and prevent harm to patients, The Guardian reports.
“These new reporting guidelines […] are a partial but valuable solution that could help catalyse a top-to-bottom transformation of healthcare,” says CCAIM Director, Professor Mihaela van der Schaar.